Essais liés11clinical trials
VilleGlasgowlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07282574

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Survodutide Maladie rénale chronique Phase 3 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) COMPLETED
Empagliflozin Maladie rénale chronique Phase 3 NCT07107945 A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) ACTIVE_NOT_RECRUITING
Edoxaban Accident vasculaire cérébral Phase 4 NCT03950076 EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF) COMPLETED
RO7268489 SEP Phase 2 NCT07282574 Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RECRUITING
Ocrelizumab SEP Phase 3 NCT03599245 This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) COMPLETED
lorundrostat Hypertension Phase 3 NCT05968430 Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT02861014 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) COMPLETED
Obecabtagene autoleucel Lupus Phase 2 NCT07053800 LUMINA — Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) RECRUITING
Deep Brain Stimulation (DBS) Parkinson À vérifier NCT02071134 Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry RECRUITING
APL-130277 Parkinson Phase 3 NCT02542696 Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease COMPLETED
Fenebrutinib SEP Phase 3 NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING